[HTML][HTML] Oncolytic virus therapy in cancer: A current review
JS Apolonio, VL de Souza Gonçalves… - World journal of …, 2021 - ncbi.nlm.nih.gov
In view of the advancement in the understanding about the most diverse types of cancer and
consequently a relentless search for a cure and increased survival rates of cancer patients …
consequently a relentless search for a cure and increased survival rates of cancer patients …
Delivery and biosafety of oncolytic virotherapy
L Li, S Liu, D Han, B Tang, J Ma - Frontiers in oncology, 2020 - frontiersin.org
In recent years, oncolytic virotherapy has emerged as a promising anticancer therapy.
Oncolytic viruses destroy cancer cells, without damaging normal tissues, through virus self …
Oncolytic viruses destroy cancer cells, without damaging normal tissues, through virus self …
Clinical application of oncolytic viruses: a systematic review
M Cook, A Chauhan - International journal of molecular sciences, 2020 - mdpi.com
Leveraging the immune system to thwart cancer is not a novel strategy and has been
explored via cancer vaccines and use of immunomodulators like interferons. However, it …
explored via cancer vaccines and use of immunomodulators like interferons. However, it …
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
R Garcia-Carbonero, R Salazar, I Duran… - … for immunotherapy of …, 2017 - Springer
Abstract Background Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric
adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study …
adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study …
Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses
K Rajani, C Parrish, T Kottke, J Thompson, S Zaidi… - Molecular Therapy, 2016 - cell.com
Oncolytic reovirus can be delivered both systemically and intratumorally, in both preclinical
models and in early phase clinical trials. Reovirus has direct oncolytic activity against a …
models and in early phase clinical trials. Reovirus has direct oncolytic activity against a …
[HTML][HTML] Oncolytic virotherapy, updates and future directions
C Fountzilas, S Patel, D Mahalingam - Oncotarget, 2017 - ncbi.nlm.nih.gov
Oncolytic viruses (OVs) are viral strains that can infect and kill malignant cells while spare
their normal counterparts. OVs can access cells through binding to receptors on their surface …
their normal counterparts. OVs can access cells through binding to receptors on their surface …
[HTML][HTML] Going viral: a review of replication-selective oncolytic adenoviruses
C Larson, B Oronsky, J Scicinski, GR Fanger, M Stirn… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Oncolytic viruses have had a tumultuous course, from the initial anecdotal reports of patients
having antineoplastic effects after natural viral infections a century ago to the development of …
having antineoplastic effects after natural viral infections a century ago to the development of …
Past, present and future of oncolytic reovirus
L Müller, R Berkeley, T Barr, E Ilett, F Errington-Mais - Cancers, 2020 - mdpi.com
Simple Summary Within this review article the authors provide an unbiased review of the
oncolytic virus, reovirus, clinically formulated as pelareorep. In particular, the authors …
oncolytic virus, reovirus, clinically formulated as pelareorep. In particular, the authors …
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients
RA Adair, V Roulstone, KJ Scott, R Morgan… - Science translational …, 2012 - science.org
Oncolytic viruses, which preferentially lyse cancer cells and stimulate an antitumor immune
response, represent a promising approach to the treatment of cancer. However, how they …
response, represent a promising approach to the treatment of cancer. However, how they …
Pediatric cancer immunotherapy: opportunities and challenges
MF Wedekind, NL Denton, CY Chen, TP Cripe - Pediatric Drugs, 2018 - Springer
Cancer immunotherapies, widely heralded as transformational for many adult cancer
patients, are becoming viable options for selected subsets of pediatric cancer patients. Many …
patients, are becoming viable options for selected subsets of pediatric cancer patients. Many …